Asia Pacific Drug Modelling Software Market Growth and Recent Trends by 2027

The Asia Pacific drug modelling software market is expected to reach US$ 2,401.22 million by 2027 from US$ 1,252.66 million in 2019; it is estimated to grow at a CAGR of 8.8% from 2020 to 2027.

Increasing adoption of in-silico modelling tools in drug discovery, and increasing economic burden of drug discovery in the region are the key factors driving the growth of drug modelling software. However, less adoption in emerging countries is the major factor hindering the market growth in Asia Pacific.

Drug modelling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key role in the development of novel drugs. Software based methods such as molecular modelling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. In addition, appropriate implementation of these techniques may help in reducing cost of drug designing and development.

Artificial intelligence and associated technologies are making drug discovery cost-effective and quick. Leading biopharmaceutical companies have been utilizing AI platforms to accelerate the drug discovery of novel therapeutics. Various late-stage clinical trials fail due to ineffective drug targets. The integration of novel computational techniques such as artificial intelligence and cloud-based platforms within silico approaches is likely to revolutionize the overall drug discovery process. With the rapid introduction of AI in healthcare, numerous pharmaceutical companies have made investments in joint ventures with AI companies to develop better healthcare tools. These include the identification of drug targets and designing new drugs. At present, AI tools are used in screening, identifying compounds, as well as to minimize drug interactions that may cause issues later.

With the rapid introduction of AI in healthcare, numerous pharmaceutical companies have made investments in joint ventures with AI companies to develop better healthcare tools. These include the identification of drug targets and designing new drugs. Therefore, numerous partnerships between pharmaceutical industries and AI companies and government organizations were witnessed.

Moreover, a growing number of AI start-ups in drug discovery technologies is further accelerating the growth of the drug modelling software market. Exscientia, a start-up working with Sumitomo Dainippon Pharma (Japan), is using artificial intelligence to create an OCD drug, reduce the creation time from four years down to less than a year. In the field of mental health, this type of efficient drug discovery offers increased effectiveness in the treatment.

The 2019 novel coronavirus (2019-nCoV), officially named as COVID-19 by the WHO, has spread to more than 170 countries, including China prompting the WHO to declare the disease as a global pandemic. As research details emerge, the data pool grows exponentially, beyond the capacity of human intelligence alone to handle. Artificial intelligence (AI) is adept at identifying patterns from big data, and this piece will elucidate how it has become one of humanity’s ace cards in handling this crisis. Pune-based drug discovery research company Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients. Hence, such outbreaks continue, the need for new technological advanced products nationwide increases and thereby positively impacting the market.

Rest of Asia Pacific Drug Modelling Software Market, Revenue and Forecast to 2027 (US$ Mn)

ASIA PACIFIC DRUG MODELLING SOFTWARE MARKET SEGMENTATION

By Product Type

• Database
• Software
• Others

By Application

• Drug Discovery and Development
• Computational Physiological Medicine
• Disease Modeling
• Medical Imaging
• Predictive Analysis of Drug Targets
• Simulation Software
• Cellular Simulation
• Others

By Country

• India
• China
• Japan
• South Korea
• Australia

Company Profiles

• Crown Bioscience Inc (JSR life science)
• Genedata AG
• Biognos AB
• Dassault Systèmes
• Acellera

Asia Pacific Drug Modelling Software Report Scope